Unichem Laboratories Ltd Stock Falls to 52-Week Low of Rs.363.3

Recent Price Movement and Market Context

On the day in question, Unichem Laboratories Ltd’s stock price fell by 2.54%, touching an intraday low of Rs.363.3. This decline extended a two-day losing streak, during which the stock has delivered a cumulative return of -3.21%. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.

The broader market environment has also been subdued. The Sensex opened 100.91 points lower and was trading at 81,280.40, down 0.32% at the time. Notably, the Sensex has experienced a three-week consecutive decline, losing 2.75% over this period. Several sectoral indices, including NIFTY MEDIA and NIFTY REALTY, also hit new 52-week lows on the same day, indicating a cautious market sentiment.

Long-Term Performance and Relative Comparison

Over the past year, Unichem Laboratories Ltd’s stock has depreciated by 50.70%, a stark contrast to the Sensex’s positive return of 7.82% during the same timeframe. The stock’s 52-week high was Rs.757.4, underscoring the extent of the recent decline. This underperformance extends beyond the last year, with the stock lagging behind the BSE500 index over the last three years, one year, and three months.

Financial Metrics and Profitability Indicators

Unichem Laboratories Ltd’s financial profile reveals several areas of concern. The company’s Debt to EBITDA ratio stands at 4.87 times, indicating a relatively high leverage level and a constrained ability to service debt obligations. This is further reflected in the interest expense, which grew by 25.99% in the latest quarter to Rs.8.24 crores.

The debt-equity ratio at the half-year mark reached 0.21 times, the highest recorded in recent periods. Non-operating income constitutes 44.20% of the company’s profit before tax, suggesting a significant portion of earnings is derived from sources outside core business operations.

Return on Equity (ROE) averaged at a modest 1.44%, signalling limited profitability generated per unit of shareholders’ funds. This low ROE aligns with the company’s subdued net sales growth, which has averaged 12.60% annually over the past five years, a figure that falls short of robust expansion expectations in the pharmaceuticals sector.

Operational and Valuation Considerations

Despite the challenges, Unichem Laboratories Ltd has demonstrated healthy long-term growth in operating profit, which has increased at an annual rate of 37.55%. The company’s Return on Capital Employed (ROCE) is recorded at 4.9%, and it maintains an enterprise value to capital employed ratio of 1.1, indicating a valuation that is attractive relative to its capital base.

The stock currently trades at a discount compared to the average historical valuations of its peers within the Pharmaceuticals & Biotechnology sector. Over the past year, while the stock price has declined sharply, the company’s profits have risen by 419.9%, resulting in a PEG ratio of zero, which reflects the disconnect between earnings growth and share price performance.

Shareholding and Market Grade

Promoters remain the majority shareholders of Unichem Laboratories Ltd, maintaining significant control over the company’s strategic direction. The stock’s Mojo Score is 40.0, with a Mojo Grade of Sell, downgraded from Hold on 22 Jul 2025. The market capitalisation grade is rated at 3, reflecting its mid-tier market cap status within the sector.

Sector and Index Performance Context

The Pharmaceuticals & Biotechnology sector, to which Unichem Laboratories Ltd belongs, has faced mixed performance in recent months. The stock’s underperformance relative to its sector peers is notable, with the sector itself experiencing volatility amid broader market fluctuations. The Sensex’s current position below its 50-day moving average, despite the 50DMA remaining above the 200DMA, indicates a cautious market environment that has weighed on stocks like Unichem Laboratories Ltd.

Unichem Laboratories Ltd’s underperformance is further highlighted by its 1.83% lag behind the sector’s daily returns on the day it hit its 52-week low. This relative weakness underscores the challenges the company faces in regaining investor confidence and market traction.

Summary of Key Price and Performance Data

To summarise, the stock’s key price points and performance metrics as of 27 Jan 2026 are:

• New 52-week low: Rs.363.3


• Day’s low: Rs.363.3 (-2.42%)


• Day’s change: -2.54%


• Consecutive fall over two days: -3.21%


• Trading below all major moving averages (5, 20, 50, 100, 200 days)


• One-year return: -50.70%


• 52-week high: Rs.757.4

Profitability and Growth Metrics

While the company’s net sales growth has been moderate at 12.60% annually over five years, operating profit growth has been more robust at 37.55% per annum. However, the low ROE of 1.44% and high leverage ratio of 4.87 times Debt to EBITDA highlight ongoing financial constraints. The increase in interest expenses and the significant share of non-operating income in profits further complicate the earnings quality assessment.

Conclusion

Unichem Laboratories Ltd’s stock reaching a 52-week low at Rs.363.3 reflects a combination of subdued market sentiment, relative underperformance against benchmarks, and financial metrics that point to challenges in profitability and debt servicing. Despite some positive indicators such as operating profit growth and attractive valuation ratios, the stock’s current position below all key moving averages and its significant price decline over the past year illustrate the hurdles the company faces in the current market environment.

Unlock special upgrade rates for a limited period. Start Saving Now →